• |
Net profit of $175K
|
• |
94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gross profit increase vs. Q4 2024 of $2.7M
|
• |
4% Revenue increase vs. Q1 2024 of $12.5M vs. $12.1M
|
• |
50% decrease in operating expenses vs. Q1 2024 excluding the one-time Oranim revocation related losses of $3.3M vs. $6.6M and 56% decrease including Oranim
|
• |
129% increase of Non-IFRS Adjusted EBITDA profit to $0.6M vs. loss of $2.2M
|
• |
Net Profit in Q1 2025 was $0.2 million, compared to
net loss of $6 million in Q1 2024.
|
• |
Revenues for the first quarter of 2025 were $12.5
million compared to $12.1 million in the first quarter of 2024, an increase of 4%. The increase is mainly due to accelerated growth in Germany of $6.6 million and offset by decreased revenue in
Israel of $6.1 million.
|
• |
Gross profit for the first quarter of 2025 was $3.4
million, compared to $1.8 million in Q1 2024, an increase of 94%.
|
• |
Total operating expenses in Q1 2025 were $3.3 million
compared to $7.4 million in Q1 2024, a decrease of 56%.
|
• |
G&A Expenses in Q1 2025 were $2 million, compared
to $2.3 million in Q1 2024, a decrease of 14%.
|
• |
Selling and Marketing Expenses in Q1 2025 were $1.3
million, compared to $2.3 million in Q1 2024, a decrease of 44%.
|
• |
Basic and diluted Profit per Share in Q1 2025 was
$0.09, compared to a loss of $2.52 per Share in Q1 2024.
|
• |
Non-IFRS Adjusted EBITDA Profit in Q1 2025 was $0.6
million, compared to an adjusted EBITDA loss of $2.2 million in Q1 2024, an increase of 129%.
|
• |
Cash and Cash Equivalents as of March 31, 2025, were $1.4 million compared to $0.9 million in December 31, 2024.
|
• |
Total assets as of March 31, 2025, were $44.9 million,
compared to $39.2 million in December 31, 2024, an increase of 15%. The increase is mainly attributed to an increase of $2.9 million in trade receivables and an increase of $2.2 million in Inventory.
|
• |
Total Liabilities as of March 31, 2025, were $41.8 million, compared to $36 in December 31, 2024, an increase of 16%. The increase is mainly attributed to an increase of $4.9 million in trade payables, an increase of
$3.7 million in other accounts payable and offset by a decrease of $2.4 million due to reduction in Credit from bank institutions and others and long term credit.
|
March 31, 2025
|
December 31, 2024
|
||||||||||
Note
|
(Unaudited)
|
||||||||||
ASSETS
|
|||||||||||
CURRENT ASSETS:
|
|||||||||||
Cash
|
$
|
1,389
|
$
|
863
|
|||||||
Restricted cash deposit
|
64
|
64
|
|||||||||
Trade receivables
|
16,653
|
13,803
|
|||||||||
Other current assets
|
5,981
|
5,419
|
|||||||||
Inventory
|
3
|
5,433
|
3,215
|
||||||||
29,520
|
23,364
|
||||||||||
NON-CURRENT ASSETS:
|
|||||||||||
Investments in affiliate
|
1,598
|
1,631
|
|||||||||
Property, plant and equipment, net
|
3,752
|
3,730
|
|||||||||
Intangible assets, net
|
3,012
|
3,333
|
|||||||||
Goodwill
|
6,540
|
6,679
|
|||||||||
Right-of-use assets, net
|
512
|
451
|
|||||||||
15,414
|
15,824
|
||||||||||
Total assets
|
$
|
44,934
|
$
|
39,188
|
March 31, 2025
|
December 31, 2024
|
||||||||||
Note
|
(Unaudited)
|
||||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY
|
|||||||||||
CURRENT LIABILITIES:
|
|||||||||||
Current maturities of operating lease liabilities
|
$
|
306
|
$
|
262
|
|||||||
Trade payables
|
16,036
|
11,159
|
|||||||||
Other current liabilities
|
8,677
|
5,001
|
|||||||||
Credit from bank institutions and others
|
12,916
|
15,145
|
|||||||||
Convertible debentures
|
2,042
|
1,968
|
|||||||||
Derivative warrants liabilities and prefunded warrants
|
4
|
817
|
1,383
|
||||||||
40,794
|
34,918
|
||||||||||
NON-CURRENT LIABILITIES:
|
|||||||||||
Operating lease liabilities
|
200
|
171
|
|||||||||
Credit from bank institutions and others
|
314
|
466
|
|||||||||
Deferred tax liabilities
|
453
|
487
|
|||||||||
967
|
1,124
|
||||||||||
Total liabilities
|
41,761
|
36,042
|
|||||||||
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:
|
5
|
||||||||||
Share capital and premium
|
265,000
|
265,000
|
|||||||||
Capital reserve from translation differences of foreign operations
|
(1,502
|
)
|
(1,265
|
)
|
|||||||
Conversion feature related to convertible debentures
|
297
|
297
|
|||||||||
Capital reserve from share-based payment transactions
|
158
|
150
|
|||||||||
Accumulated deficit
|
(258,629
|
)
|
(258,939
|
)
|
|||||||
Total equity attributable to equity holders of the Company
|
5,324
|
5,243
|
|||||||||
Non-controlling interests
|
(2,151
|
)
|
(2,097
|
)
|
|||||||
Total equity
|
3,173
|
3,146
|
|||||||||
Total liabilities and equity
|
$
|
44,934
|
$ |
39,188
|
Three months ended
March 31,
|
|||||||||||
Note
|
2025
|
2024
|
|||||||||
Revenues
|
$
|
12,500
|
$
|
12,063
|
|||||||
Cost of revenues
|
9,052
|
10,274
|
|||||||||
Gross profit before fair value adjustments
|
3,448
|
1,789
|
|||||||||
Fair value adjustments:
|
|||||||||||
Realized fair value adjustments on inventory sold in the period
|
-
|
(10
|
)
|
||||||||
Total fair value adjustments
|
-
|
(10
|
)
|
||||||||
Gross profit
|
3,448
|
1,779
|
|||||||||
General and administrative expenses
|
2,009
|
2,332
|
|||||||||
Selling and marketing expenses
|
1,273
|
2,292
|
|||||||||
Share-based compensation
|
8
|
32
|
|||||||||
Other operating expenses
|
9
|
-
|
2,753
|
||||||||
Total operating expenses
|
3,290
|
7,409
|
|||||||||
Operating income (loss)
|
158
|
(5,630
|
)
|
||||||||
Finance expense, net
|
4
|
(12
|
)
|
(501
|
)
|
||||||
income (loss) before income taxes
|
146
|
(6,131
|
)
|
||||||||
Income tax benefit
|
29
|
111
|
|||||||||
Net income (loss)
|
$
|
175
|
$
|
(6,020
|
)
|
Three months ended
March 31,
|
|||||||||||
Note
|
2025
|
2024 (*)
|
|
||||||||
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:
|
|||||||||||
Total other comprehensive income that will not be reclassified to profit or loss in subsequent periods
|
35
|
67
|
|||||||||
Exchange differences on translation to presentation currency
|
-
|
1,330
|
|||||||||
Total other comprehensive income (loss) that will not be reclassified to profit or loss in subsequent periods
|
35
|
1,397
|
|||||||||
Other comprehensive income that will be reclassified to profit or loss in subsequent periods:
|
|||||||||||
Adjustments arising from translating financial statements of foreign operation
|
(191
|
)
|
(35
|
)
|
|||||||
Total other comprehensive income (loss) that will be reclassified to profit or loss in subsequent periods
|
(191
|
)
|
(35
|
)
|
|||||||
Total other comprehensive income (loss)
|
(156
|
)
|
1,362
|
||||||||
Total comprehensive income (loss)
|
$
|
19
|
$
|
(4,658
|
)
|
||||||
Net income (loss) attributable to:
|
|||||||||||
Equity holders of the Company
|
275
|
(5,623
|
)
|
||||||||
Non-controlling interests
|
(100
|
)
|
(397
|
)
|
|||||||
$
|
175
|
$
|
(6,020
|
)
|
|||||||
Total comprehensive income (loss) attributable to:
|
|||||||||||
Equity holders of the Company
|
73
|
(4,252
|
)
|
||||||||
Non-controlling interests
|
(54
|
)
|
(406
|
)
|
|||||||
$
|
19
|
$
|
(4,658
|
)
|
|||||||
Net income (loss) per share attributable to equity holders of the Company:
|
7
|
||||||||||
Basic and diluted income (loss) per share (in CAD)
|
$
|
0.09
|
$
|
(2.52
|
)
|
(*) |
Loss per share includes the effect of Reverse Share Split (see also Note 5a below).
|
Share capital and premium
|
Reserve from share-based payment transactions
|
Conversion option for convertible debt
|
Translation reserve
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
equity
|
|||||||||||||||||||||||||
Balance as of January 1, 2025
|
$
|
265,000
|
$
|
150
|
$
|
297
|
$
|
(1,265
|
)
|
$
|
(258,939
|
)
|
$
|
5,243
|
$
|
(2,097
|
)
|
$
|
3,146
|
|||||||||||||
Net income (Loss)
|
-
|
-
|
-
|
-
|
275
|
275
|
(100
|
)
|
175
|
|||||||||||||||||||||||
Total other comprehensive income (loss)
|
-
|
-
|
-
|
(237
|
)
|
35
|
(202
|
)
|
46
|
(156
|
)
|
|||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
-
|
(237
|
)
|
310
|
73
|
(54
|
)
|
19
|
||||||||||||||||||||||
Share-based compensation
|
-
|
8
|
-
|
-
|
8
|
-
|
8
|
|||||||||||||||||||||||||
Balance as of March 31, 2025
|
$
|
265,000
|
$
|
158
|
$
|
297
|
$
|
(1,502
|
)
|
$
|
(258,629
|
)
|
$
|
5,324
|
$
|
(2,151
|
)
|
$
|
3,173
|
Share
Capital and premium
|
Reserve from share-based payment transactions
|
Translation reserve
|
Accumulated deficit
|
Total
|
Non-controlling interests
|
Total
equity
|
||||||||||||||||||||||
Balance as of January 1, 2024
|
$
|
253,882
|
$
|
9,637
|
$
|
95
|
$
|
(249,145
|
)
|
$
|
14,469
|
$
|
(769
|
)
|
$
|
13,700
|
||||||||||||
Net loss
|
-
|
-
|
-
|
(5,623
|
)
|
(5,623
|
)
|
(397
|
)
|
(6,020
|
)
|
|||||||||||||||||
Total other comprehensive loss
|
-
|
-
|
1,304
|
67
|
1,371
|
(9
|
)
|
1,362
|
||||||||||||||||||||
Total comprehensive loss
|
-
|
-
|
1,304
|
(5,556
|
)
|
(4,252
|
)
|
(406
|
)
|
(4,658
|
)
|
|||||||||||||||||
Other comprehensive income Classification
|
-
|
-
|
-
|
(730
|
)
|
(730
|
)
|
-
|
(730
|
)
|
||||||||||||||||||
Share-based compensation
|
-
|
32
|
-
|
-
|
32
|
-
|
32
|
|||||||||||||||||||||
Forfeited options
|
5
|
(5
|
)
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||
Balance as of March 31, 2024
|
$
|
253,887
|
$
|
9,664
|
$
|
1,399
|
$
|
(255,431
|
)
|
$
|
9,519
|
$
|
(1,175
|
)
|
$
|
8,344
|
Three months ended
March 31,
|
||||||||
2025
|
2024
|
|||||||
Cash provided by operating activities:
|
||||||||
Net income (loss)
|
$
|
175
|
$
|
(6,020
|
)
|
|||
Adjustments for non-cash items:
|
||||||||
Fair value adjustment on sale of inventory
|
-
|
10
|
||||||
Fair value adjustment on Warrants, investments and accounts receivable
|
(565
|
)
|
100
|
|||||
Interest recorded in respect of the convertible debt
|
73
|
-
|
||||||
Depreciation of property, plant and equipment
|
46
|
147
|
||||||
Amortization of intangible assets
|
338
|
452
|
||||||
Depreciation of right-of-use assets
|
79
|
118
|
||||||
Impairment of PPE
|
-
|
2,753
|
||||||
Finance expenses, net
|
504
|
401
|
||||||
Deferred tax liability, net
|
(40
|
)
|
(69
|
)
|
||||
Share-based payment
|
8
|
32
|
||||||
Discount expenses in respect of credit
|
36
|
-
|
||||||
479
|
3,944
|
|||||||
Changes in working capital:
|
||||||||
Increase (decrease) in trade receivables
|
(3,245
|
)
|
1,332
|
|||||
Increase (decrease) in other accounts receivable and advances to suppliers
|
(1,405
|
)
|
159
|
|||||
Increase (decrease) in inventories, net of fair value adjustments
|
(2,349
|
)
|
2,159
|
|||||
Increase in trade payables
|
5,270
|
663
|
||||||
Increase (decrease) in other accounts payable and accrued expenses
|
5,544
|
(2,745
|
)
|
|||||
3,815
|
1,568
|
|||||||
Taxes paid
|
(6
|
)
|
(121
|
)
|
||||
Net cash provided (used) in operating activities
|
4,463
|
(629
|
)
|
|||||
Cash flows from investing activities:
|
||||||||
Purchase of property, plant and equipment
|
-
|
(2
|
)
|
|||||
Net cash used in investing activities
|
$
|
-
|
$
|
(2
|
)
|
Three months ended
March 31,
|
||||||||
2025
|
2024
|
|||||||
Cash flow from financing activities:
|
||||||||
Proceeds from issuance of share capital, net of issuance costs
|
-
|
176
|
||||||
Proceeds from issuance of warrants
|
-
|
(176
|
)
|
|||||
Repayment of lease liability
|
(68
|
)
|
(118
|
)
|
||||
Interest paid - lease liability
|
(10
|
)
|
(15
|
)
|
||||
Repayment of bank loan and credit facilities
|
(594
|
)
|
(2,856
|
)
|
||||
Cash paid for interest
|
(976
|
)
|
(444
|
)
|
||||
Proceeds (repayments) from discounted checks
|
(1,224
|
)
|
2,581
|
|||||
Net cash provided (used) by financing activities
|
(2,872
|
)
|
(852
|
)
|
||||
Effect of foreign exchange on cash and cash equivalents
|
(1,065
|
)
|
718
|
|||||
Increase (decrease) in cash and cash equivalents
|
526
|
(765
|
)
|
|||||
Cash and cash equivalents at the beginning of the period
|
863
|
1,813
|
||||||
Cash and cash equivalents at end of the period
|
$
|
1,389
|
$
|
1,048
|
||||
Supplemental disclosure of non-cash activities:
|
||||||||
Right-of-use asset recognized with corresponding lease liability
|
$
|
159
|
$
|
40
|